HALO
HALOZYME THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$112.45
+2.53%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$110.33
From 52W high+0.00%
Volume10.03M
Market cap$12.76B
P/E (TTM)31.9x
P/S (TTM)7.7x
Div yield—
Key dataSep 18, 2026
Open
$110.33
From 52W high
+0.00%
Volume
10.03M
Market cap
$12.76B
ValuationView details →
P/E (Fwd)
11.8x
EV/EBITDA
20.6x
P/E (TTM)
31.9x
RSI (14)
68.4
MomentumView details →
1D Return
+2.53%
YTD Return
+65.58%
SummaryUpdated Jun 1, 2026
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a San Diego-based biopharma technology platform company founded in 1998 that went public in 2004. The company has evolved from a traditional biotechnology firm into a specialized drug delivery technology platform, leveraging its proprietary ENHANZE technology to enable pharmaceutical companies to convert intravenous biologics into more convenient subcutaneous formulations. Over the past decade, Halozyme has transformed its business model from primarily developing its own drugs to licensing its platform technology to major pharmaceutical partners, creating a highly scalable and profitable royalty-based revenue stream.
Similar companies
Latest newsMore news →
Halozyme Therapeutics announced a proposed offering of $1.05 billion aggregate principal amount of convertible senior notes due 2033.4d agoHalozyme Therapeutics reported record second-quarter fiscal 2026 revenue of $481 million, up 48% year over year, with non-GAAP diluted EPS of $1.90, and raised its full-year 2026 guidance.9d ago